Biostem Technologies Osake

Biostem Technologies EBITDA

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Biostem Technologies (BSEM) 1.8.2026 päivämäärällä on 31,42 M USD. Edellisenä vuonna EBITDA (Tulos ennen korkoja, veroja ja poistoja) oli −7,55 M USD — muutos −516,18 % (korkeampi).

EBITDA

31,42 MUSD

YoY

−516,18%

Viimeksi päivitetty:

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Biostem Technologies on 2026 31,42 M USD. EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Biostem Technologies oli 2025 −7,55 M USD. Se laskee −516,18% korkeampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

Biostem Technologies Osakeanalyysi

Mitä Biostem Technologies tekee? Biostem Technologies Inc is a US company specializing in regenerative medicine. It was founded in 2007 and is based in Clearwater, Florida. Biostem Technologies is listed on the OTCQB Stock Exchange and offers a wide range of products in the field of regenerative medicine. The company's business model primarily involves advancing growth in the field of regenerative medicine through the development and marketing of new products and technologies. They focus on the production of stem cells that can be used in the regeneration of damaged tissues and organs. They also offer research and development of stem cell therapies, manufacturing of stem cell products, and related services. Biostem Technologies places emphasis on processing umbilical cord blood stem cells, collaborating with medical facilities to collect and isolate these cells for preservation. The company has also developed products such as BioStem Serum and BioStem Gel, made from stem cells and used in regeneration and wound healing. They have developed technologies for regenerating damaged tissues and organs, including a technology for regenerating muscle and adipose tissue through stem cell injection. Clinical studies have shown promising results with this technology. Biostem Technologies has partnerships with other companies and institutes in the field of regenerative medicine, including working with the National Institute of Neurological Disorders and Stroke to develop a new therapy for multiple sclerosis. They also provide consulting services to assist other companies in developing regenerative products and services. In conclusion, Biostem Technologies is a leading company in the field of regenerative medicine and stem cell therapies, offering a range of products and services. They also provide important technologies for tissue regeneration, positioning them as a key player in the field of regenerative medicine. Biostem Technologies on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Biostem Technologies osakkeesta

Yhtiön Biostem Technologies EBITDA (Tulos ennen korkoja, veroja ja poistoja) on 31,42 M USD vuonna 2026.

Access this data via the Eulerpool API

Tuloslaskelma — Biostem Technologies

Kaikki tunnusluvut — Biostem Technologies